KEYNOTE-811: First-line Pembrolizumab + Trastuzumab and Chemotherapy in HER2+ Metastatic Gastric or Gastroesophageal Junction Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
Interim analysis of the KEYNOTE-811 trial shows significantly higher response rate and more durable responses with pembrolizumab added to first-line trastuzumab and chemotherapy in gastric or gastroesophageal junction cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 412 KB
Released: June 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Phase I/II ReFocus: RLY-4008 in patients with FGFR inhibitor-naive cholangiocarcinoma with FGFR2 alterations, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

Primary results from phase III LEAP-002 study of lenvatinib with or without pembrolizumab as first-line treatment for patients with advanced hepatocellular carcinoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 19, 2022

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings